| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 39.68% | -7.7% | 4.01% | 91/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 38.15% | -12.87% | -4.43% | 98/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 39.92% | -14.53% | -4.89% | 95/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 41.97% | -8.9% | -2.37% | 99/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 42.99% | -9.87% | -1.81% | 92/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 43.79% | -7.66% | -6.25% | 91/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 46.71% | -4.47% | 1.37% | 82/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.07% | 6.63% | -3.41% | 92/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 47.7% | 10.4% | 0.59% | 84/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 47.42% | 9.06% | -3.01% | 88/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 48.89% | 8.9% | 13.15% | 79/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 43.21% | -1.14% | 0.01% | 96/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 43.2% | -15.02% | -0.63% | 92/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 43.48% | -17.45% | -3.15% | 94/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 44.89% | -22.8% | 2.72% | 82/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 43.71% | -21.47% | -14.03% | 93/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 50.84% | -11.23% | -3.48% | 72/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 52.67% | -7.61% | -9.42% | 75/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 58.15% | 12.98% | 4.49% | 55/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 55.66% | 8.48% | -2.82% | 68/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 57.27% | 9.87% | 0.45% | 57/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 57.01% | 10.33% | 10.76% | 57/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 51.47% | 3.18% | 0.32% | 61/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 51.31% | 4.52% | -1.57% | 73/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 52.12% | 2% | 0.87% | 58/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 51.67% | 4.98% | 3.59% | 60/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 49.88% | 2% | 1.62% | 56/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 49.09% | 0.44% | -0.27% | 73/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 49.22% | 0.11% | 0.71% | 55/159 | 53.39% | 贝达药业 | 95.47% | 行业排名> |
| 2017-12-31 | 48.87% | 3.52% | -0.59% | 65/159 | 52.32% | 贝达药业 | 95.51% | 行业排名> |
| 2017-06-30 | 49.16% | 2% | 4.13% | 48/159 | 47.74% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 47.21% | 23.45% | 23.45% | 53/159 | 48.19% | 贝达药业 | 95.74% | 行业排名> |
| 2015-12-31 | 38.25% | -1.58% | -1.58% | 60/159 | 45.97% | 退市金泰 | 96.19% | 行业排名> |

微信公众号
证券之星APP



